FDA reversal sends mixed message to multiple sclerosis community

The agency's approval of alemtuzumab leaves neurologists wondering when unblinded studies are appropriate for pivotal multiple sclerosis trials.

Enjoying our latest content?
Log in or create an account to continue

• Access the most recent journalism from Nature's award-winning team
• Explore the latest features & opinion covering groundbreaking research

Access through your institution

or

Sign in or create an account

Continue with Google

Continue with ORCiD